Despite the vast number of trials taking place within the NSCLC space it remains one of the highest tumor indications of unmet clinical need, with prevalence only set to increase. Focusing from late-line through to early-line, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC.
There has never been a more important time to attend the 2nd NSCLC Drug Development Summit. Join this dedicated and determined community uniting to defeat NSCLC and radically change patients’ lives.
What Will We Cover?
Explore the realm of targeted therapies within NSCLC with clinical updates in an array of actionable mutations with Mirati Therapeutics, Blueprint Medicines, Merus, Iteron Tx, Kinnate & Verastem
Understand developments in the IO space and how cutting-edge developers are overcoming challenges of patient selection with Sanofi, Molecular Templates, Xcovery & Georgetown University
Unlock the latest in the checkpoint space, with rationale and updates in combination strategy and addressing resistance and adjuvant/ neoadjuvant conversations with Merck & Co, Bristol-Myers Squibb & Immutep
Delve into optimizing clinical trial design, moving your drug into earlier lines and various stages of the disease with Georgetown University & LUNGevity Foundation
Connect in person with your peers, ask your burning questions, build connections, and fully immerse yourself in the world of NSCLC drug development